With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...
Nutrien Ltd. (TSX and NYSE: NTR) today announced the pricing of US$400 million aggregate principal amount of 4.500 percent ...
Trinity Biotech (TRIB) announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose ...
Zacks Investment Research on MSN8d
Barclays Shares Hit a 5-Year High: Is BCS Worth Betting on?During yesterday’s trading session, Barclays BCS stock touched a new 5-year high of $16.27 on the NYSE. In the past six ...
TipRanks on MSN4d
Barclays Executes Share Buy-Back to Optimize Capital StructureBarclays ( ($GB:BARC) ) has provided an announcement. Barclays PLC has announced the purchase and cancellation of 5,155,000 of its ordinary shares ...
Barclays has hired John Kolz from RBC Capital Markets to be global co-head of equity capital markets in New York. Barclays ...
Trinity Biotech, a commercial-stage biotech company focused on human diagnostics and diabetes management solutions, including wearable biosensors, has appointed Barclays Capital as its exclusive finan ...
Barclays Plc hired John Kolz from Royal Bank of Canada to co-run global equity capital markets as it looks to the business to ...
This will support Barclays financially by freeing up significant capital, improving its balance sheet and enabling better resource allocation to high-growth areas. Further, as part of the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback